Article published by Sean Gill, Principal Behavioral Scientist, S3 Connected Health on PharmaPhorum on 22 January 2019.
How digital technologies and behavioral science create adherence programs that work at scale.
Developing drugs is only half the battle. With the pharma industry under increasing pressure to show real-world outcomes, a new frontier has emerged beyond the prescription in the unchartered waters of human behavior.
Read the full article published in PharmaPhorum
We take a look at the traditional approach at addressing unintentional non-adherence and how digitally enhanced patient support programs can apply a behavioral lens to address the challenges posed by unintentional non-adherence.